MedTrace Logo

Cardiovascular Magnetic Resonance for the Occluded Infarct-Related Artery Treatment

NCT00968383 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2015-05-14

No results posted yet for this study

Summary

The purpose of this study is to determine whether opening an occluded infarcted artery 3-28 days after an acute myocardial infarction in high-risk asymptomatic patients with preserved infarct zone viability improves left ventricular systolic function and volumes at 6 months follow-up. The secondary purpose is to assess the changes in myocardial tissue characteristics after late percutaneous coronary intervention (PCI).

Conditions

Interventions

DRUG

Beta adrenergic blockers

Participants will receive beta adrenergic blockers.

DRUG

Platelet inhibitors

Participants will receive platelet inhibitors.

DRUG

Statins

Participants will receive statins.

DRUG

ACE inhibitors and/or ARB and/or AA

Participants will receive ACE inhibitors and/or ARB and/or AA

PROCEDURE

PCI with stenting

Participants will undergo percutaneous coronary intervention (PCI) and coronary stenting.

Sponsors & Collaborators

  • National Institute of Cardiology, Warsaw, Poland

    lead OTHER

Principal Investigators

  • Lukasz A Malek, M.D. PhD · National Institute of Cardiology, Warsaw, Poland

  • Mariusz Kruk, M.D. PhD · National Institute of Cardiology, Warsaw, Poland

  • Mariusz Klopotowski, M.D. · National Institute of Cardiology, Warsaw, Poland

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-09-30
Primary Completion
2012-12-31
Completion
2012-12-31

Countries

  • Poland

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00968383 on ClinicalTrials.gov